INCY Incyte Corp.
5,171
$53.06
$0.44
(0.82%)
| Watchers | 5,171 |
| 52-Wk Low | $50.27 |
| 52-Wk High | $67.37 |
| Market Cap | $11.91B |
| Volume | 1.51M |
| 52-Wk High | $67.37 |
| 52-Wk Low | $50.27 |
Incyte to Present at Upcoming Investor ConferenceBusiness Wire • 10 days ago
Incyte (Nasdaq:INCY) announced today that it will present at the Bank of America Securities 2024 Health Care Conference on Wednesday, May 15, 2024 at 8:00 a.m. (PDT) in Las Vegas. The presentation...
Share to Feed
Incyte (Nasdaq:INCY) today reports 2024 first quarter financial results, and provides a status update on the Companys clinical development portfolio. 'In the first quarter of 2024, total revenues...
Incyte (Nasdaq:INCY) announced today that it has scheduled its first quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, April 30, 2024. The schedule for the press...
Trust Point Inc. bought a new stake in Incyte Co. (NASDAQ:INCY - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
Incyte (Nasdaq:INCY) (Incyte) and China Medical System Holdings Limited (CMS or the Group) are pleased to announce that on March 31, 2024, Incyte and CMS, through a wholly-owned dermatology medical...
Povorcitinib, a selective oral JAK1 inhibitor discovered by Incyte, is an investigational medicine being evaluated for the treatment of non-segmental vitiligo, hidradenitis suppurativa (HS), prurigo...
In this piece, we will take a look at the 12 best S&P 500 stocks to buy according to analysts. If you want to skip our coverage of the latest happenings surrounding one of America's most widely...
Incyte (Nasdaq:INCY) announced today that it granted equity inducement awards to Matteo Trotta, the Companys new Executive Vice President and General Manager of U.S. Dermatology, pursuant to the...